594 related articles for article (PubMed ID: 26463142)
1. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
[TBL] [Abstract][Full Text] [Related]
2. Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth.
Qu FL; Xia B; Li SX; Tian C; Yang HL; Li Q; Wang YF; Yu Y; Zhang YZ
Cancer Biol Med; 2015 Dec; 12(4):401-8. PubMed ID: 26779377
[TBL] [Abstract][Full Text] [Related]
3. [Effect of PI3Kδ inhibitor CAL-101 on myeloma cell lines and preliminary study of synergistic effects with other new drugs].
Zhang Q; Xia B; Qu F; Yuan T; Guo S; Zhao W; Li Q; Yang H; Wang Y; Zhang Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Oct; 35(10):926-30. PubMed ID: 25339332
[TBL] [Abstract][Full Text] [Related]
4. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
5. Puerarin induced in mantle cell lymphoma apoptosis and its possible mechanisms involving multi-signaling pathway.
Gan M; Yin X
Cell Biochem Biophys; 2015 Jan; 71(1):367-73. PubMed ID: 25173778
[TBL] [Abstract][Full Text] [Related]
6. Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.
Yang Q; Chen LS; Ha MJ; Do KA; Neelapu SS; Gandhi V
Clin Cancer Res; 2017 Jan; 23(1):181-192. PubMed ID: 27342398
[TBL] [Abstract][Full Text] [Related]
7. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S
Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.
Zhao LL; Liu YF; Peng LJ; Fei AM; Cui W; Miao SC; Hermine O; Gressin R; Khochbin S; Chen SJ; Wang J; Mi JQ
Cancer Med; 2015 Nov; 4(11):1754-66. PubMed ID: 26310857
[TBL] [Abstract][Full Text] [Related]
9. Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways.
Rizzatti EG; Mora-Jensen H; Weniger MA; Gibellini F; Lee E; Daibata M; Lai R; Wiestner A
Leuk Lymphoma; 2008 Apr; 49(4):798-808. PubMed ID: 18398749
[TBL] [Abstract][Full Text] [Related]
10. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
Pham LV; Tamayo AT; Li C; Bornmann W; Priebe W; Ford RJ
Mol Cancer Ther; 2010 Jul; 9(7):2026-36. PubMed ID: 20606045
[TBL] [Abstract][Full Text] [Related]
11. [Effects of Decitabine Combined with Bortezomib on the Proliferation of Mantle Cell Lymphoma Cell Lines and Its Underling Mechanisms].
Zhang JN; Qiao SK; Chen D; Xing LN; Li Y; Guo XN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1197-1204. PubMed ID: 32798398
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of bortezomib-induced apoptosis by TGF-beta in cultured human Tenon's fibroblasts: contribution of the PI3K/Akt signaling pathway.
Chung EJ; Moon SW; Jung SA; Cho YJ; Kim SW; Lee JH
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6232-7. PubMed ID: 20702821
[TBL] [Abstract][Full Text] [Related]
14. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
Shirsath NP; Manohar SM; Joshi KS
Mol Cancer; 2012 Oct; 11():77. PubMed ID: 23075291
[TBL] [Abstract][Full Text] [Related]
15. [Reversal effect of LBH589 alone or in combination with bortezomib on drug-resistance in myeloid leukemia and its mechanism].
Jiang XJ; Meng FY; Zhou HS; Wang Q; Wu FQ; Huang KK; Huang M; Wang ZX; Chen WW
Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):537-42. PubMed ID: 22338177
[TBL] [Abstract][Full Text] [Related]
16. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.
Sun L; Zhang L; Qian J; Yang J; Yi Q; Dong W; Wang M
Leuk Res; 2012 Mar; 36(3):363-8. PubMed ID: 22000823
[TBL] [Abstract][Full Text] [Related]
17. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
[TBL] [Abstract][Full Text] [Related]
18. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA
MAbs; 2009; 1(1):31-40. PubMed ID: 20046572
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.
Cowan AJ; Frayo SL; Press OW; Palanca-Wessels MC; Pagel JM; Green DJ; Gopal AK
Anticancer Drugs; 2015 Oct; 26(9):974-83. PubMed ID: 26237500
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma.
Lyu MA; Pham LV; Sung B; Tamayo AT; Ahn KS; Hittelman WN; Cheung LH; Marks JW; Cho MJ; Ford RJ; Aggarwal BB; Rosenblum MG
Biochem Pharmacol; 2012 Aug; 84(4):451-8. PubMed ID: 22687624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]